The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Subscribe To Our Newsletter & Stay Updated
